EN | RU
EN | RU

Help Support

Back

Taroxaz-104 shows efficacy against new strain of SARS-CoV-2

Taroxaz-104 shows efficacy against new strain of SARS-CoV-2 Taroxaz-104 shows efficacy against new strain of SARS-CoV-2
Taroxaz-104 shows efficacy against new strain of SARS-CoV-2 Taroxaz-104 shows efficacy against new strain of SARS-CoV-2

What's new?

Taroxaz-104 showed significant inhibitory activity against new strains/variants of coronavirus (VOC-202012/01).

In a recent study published in "Chemico-Biological Interactions", Taroxaz-104 was found to exert potent toxic effects on the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and also showed good efficacy against the newly evolved strains/variants of coronavirus such as VOC-202012/01.  Amgad M. Rabie undertook this study for computationally screening and examining the library of previously-synthesized oxadiazoles against the coronavirus protein targets.

Taroxaz-104 demonstrated considerably low binding energies with nCoV-RdRp-RNA and nCoV-RdRp alone. These binding energies were reported to be substantially reduced when compared with the standard reference drug GS-443902 (remdesivir potent active metabolite), as shown below:


Taroxaz-104 was found to exhibit about 43-fold anti-SARS-CoV-2 potencies as compared to GS-443902. Additional computational molecular assessment illustrated that this antioxidant ligand actively suppresses one of the important active sites of nCoV-RdRp (GS-443902 majorly interacts with this site). This is because it interacts with at least seven active amino acid residues of its predicted pocket.

Following the potential findings of the anti-COVID-19 biological assay, the successful repurposing of Taroxaz-104 has been achieved. It successfully suppressed the most crucial stage of the coronaviral-2 life cycle, the multiplication/transcription phase, with an anti-SARS-CoV-2 EC50 value [half maximal effective concentration]  of 0.42 μM.

Thus, Taroxaz-104, a promising anti-COVID-19 agent, is also the first reported anti-VOC-202012/01 agent.  

Source:

Chemico-Biological Interactions

Article:

Potent Toxic Effects of Taroxaz-104 on the Replication of SARS-CoV-2 Particles

Authors:

Amgad M. Rabie

Comments (0)

Recommendations

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: